Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial

• Published in: Hepatology (Baltimore, Md.) Vol. 80; no. 4; pp. 916 - 927
• Main Authors: Cheung, Ka Shing, Ng, Ho Yu, Hui, Rex Wan Hin, Lam, Lok Ka, Mak, Lung Yi, Ho, Yuen Chi, Tan, Jing Tong, Chan, Esther W., Seto, Wai Kay, Yuen, Man Fung, Leung, Wai K.
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.10.2024
• Subjects: Adult; Aged; Benzhydryl Compounds - therapeutic use; Double-Blind Method; Female; Glucosides - therapeutic use; Humans; Liver - diagnostic imaging; Liver - drug effects; Liver - pathology; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - diagnostic imaging; Non-alcoholic Fatty Liver Disease - drug therapy; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Treatment Outcome

Background and Aims: We investigated whether empagliflozin reduces hepatic steatosis in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus. Approach and Results: This was an investigator-initiated, double-blind, randomized, placebo-controlled trial recru...